Targeted Oncology: Treatment approaches become more individualized as field of myelofibrosis advances

In this interview, Ruben Mesa, MD, director of the Mays Cancer Center, shares highlights from his presentation on the role of JAK inhibitors in myelofibrosis during the first annual Texas Virtual MPN Workshop and Meeting.

Read the story.

Share This Article!